Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic ...

Cite this: ASCO 2025: Highlights in Prostate Cancer Biomarkers and Therapies - Medscape - June 06, 2025.

The company announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial on June 2, reporting that the trial met its primary endpoint.

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic ...

The company recently shared topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, in which Pluvicto plus standard of care (SoC) treatment demonstrated a benefit ...

The company announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial on June 2, reporting that the trial met its primary endpoint. It demonstrated a ...

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3.

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

The company recently shared topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, in which Pluvicto plus standard of care (SoC) treatment demonstrated a benefit in ...